IDXX
IDEXX Laboratories Inc
NASDAQ: IDXX · HEALTHCARE · DIAGNOSTICS & RESEARCH
$553.66
-2.58% today
Updated 2026-04-29
Market cap
$44.08B
P/E ratio
42.36
P/S ratio
10.24x
EPS (TTM)
$13.07
Dividend yield
—
52W range
$465 – $770
Volume
0.5M
IDEXX Laboratories Inc (IDXX) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $559.56M | $702.18M | $765.44M | $808.53M | $897.14M | $1.03B | $1.10B | $1.23B | $1.38B | $1.47B | $1.53B | $1.71B | $1.54B | $1.83B | $2.29B | $2.44B | $2.75B | $3.26B | $3.29B | $3.35B |
| Cash & equivalents | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Current assets | $302.26M | $305.66M | $355.89M | $376.34M | $460.59M | $524.23M | $569.54M | $652.71M | $759.40M | $821.63M | $845.58M | $971.99M | $654.17M | $679.64M | $1.06B | $955.65M | $1.10B | $1.50B | $1.40B | $1.41B |
| Total liabilities | $149.70M | $263.86M | $327.24M | $293.95M | $322.86M | $491.22M | $467.35M | $712.30M | $1.27B | $1.56B | $1.64B | $1.77B | $1.55B | $1.65B | $1.66B | $1.75B | $2.14B | $1.78B | $1.70B | $1.75B |
| Current liabilities | $124.74M | $223.39M | $295.29M | $256.31M | $285.11M | $436.88M | $406.33M | $478.35M | $820.91M | $856.76M | $934.57M | $1.00B | $770.44M | $725.34M | $582.76M | $763.58M | $1.24B | $951.55M | $1.07B | $1.15B |
| Long-term debt | $6.45M | $5.73M | $5.09M | $4.28M | $3.42M | $2.50M | $1.39M | $150.36M | $350.00M | $597.09M | $593.11M | $606.08M | $601.35M | $698.91M | $858.49M | $775.21M | $694.39M | $622.88M | $449.79M | — |
| Shareholder equity | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Retained earnings | $490.61M | $585.86M | $702.03M | $824.26M | $965.54M | $1.13B | $1.31B | $1.49B | $1.68B | $318.36M | $540.40M | $803.54M | $1.17B | $1.60B | $2.18B | $2.92B | $3.60B | $4.44B | $5.33B | — |
| Accounts receivable | $81.39M | $108.38M | $111.50M | $115.11M | $120.08M | $141.28M | $138.32M | $158.04M | $181.31M | $200.11M | $232.17M | $270.07M | $258.52M | $307.49M | $374.74M | $425.58M | $490.90M | $529.53M | $473.57M | $552.38M |
| Inventory | $96.00M | $98.80M | $115.93M | $110.42M | $127.89M | $133.10M | $140.95M | $133.43M | $160.34M | $188.83M | $158.03M | $164.32M | $173.30M | $195.02M | $209.87M | $269.03M | $367.82M | $380.28M | $381.88M | $377.76M |
| Goodwill | $104.83M | $236.41M | $138.77M | $148.71M | $149.11M | $172.61M | $174.99M | $180.52M | $184.45M | $178.93M | $178.23M | $199.87M | $214.49M | $239.72M | $243.35M | $359.35M | $361.80M | $365.96M | $405.10M | — |